tebu-bio

tebu-bio is pleased to announce their agreement with CH3 BioSystems to distribute their product range to the European market.

Bromodomains are a new emerging class of pharmaceutical targets in the field of Epigenetics. Bromodomains (BRDs) are protein domains involved in Epigenetics that recognize acetylated lysines.

Stimulated Emission Depletion Microscopy (or STED nanoscopy) offers a technological breakthrough in the environment of cell imaging by drastically increasing the resolution over traditional confocal microscopy.

HypoThermosol® and CryoStor® Will Be Locally Available to the Broader European Research and Clinical Markets

tebu-bio and XenoTech LLC co-organize a series of webinars focused on attaching human hepatocytes in ADME-TOX studies.

The Kima™ pump is a microfluidic pump designed to aid cell culture (e.g. endothelial cells) under physiological conditions (shear flow) in various biochips and flow chambers.

tebu-bio is pleased to announce their recent distribution agreement with Sanguine BioSciences, Inc.

tebu-bio is pleased to be participating at the ELA Screening Europe conference which will take place in Hamburg from June 30th to July 1st, 2011

Signé le 21 Avril 2010, l'accord est valable jusqu'en Avril 2012 et couvre l'ensemble du catalogue général de tebu-bio.

tebu-bio is pleased to announce the renewal for another three years, of their official recognition by the French Ministry of Higher Education & Research as an approved CRO (contract research organisation) within the French Research Tax Credit scheme.